Ramot - Tel Aviv University's Tech Transfer Company

Congratulations to the outstanding Tel Aviv University student team, led by Prof. Tamir Tuller, on winning a gold medal at the prestigious iGEM Competition in Paris. Their groundbreaking project, Precise RNA Oncotherapy (PROtech), introduces a revolutionary approach to personalized cancer treatment, offering hope to patients with previously untreatable conditions. The team's innovative work combines cutting-edge synthetic biology and advanced computational models, demonstrating the immense potential of interdisciplinary collaboration. We are proud of their achievement and their contribution to shaping the future of cancer therapy. #goldmedal #iGEM #competition #cancer #cancertreatment #innovation #healthtech #healthinnovation #syntheticbiology

Influenza A is a leading cause of severe respiratory illness worldwide, with millions of cases and hundreds of thousands of deaths each year. While current treatments like Tamiflu target the viral neuraminidase (NA), new combination therapies are needed for better efficacy. Prof. Nir Ben-Tal, Prof. Eran Bacharach, Prof. Doron Shabat, and Prof. Yoni Haitin have developed promising small-molecule inhibitors that target the viral hemagglutinin (HA) protein, significantly reducing viral replication and offering potential for both monotherapy and combination therapies for influenza treatment. To learn more about this technology and its applications, please contact Tali Aloya, Ph.D., VP Business Development Life Sciences at Ramot: tali.aloya@ramot.org #influenza #virus #drugdiscovery #influenzatreatment #innovation #healthtech #medtech #healthinnovation

Identifai Genetics, a ramot spinoff, is revolutionizing prenatal care with its groundbreaking non-invasive prenatal testing (NIPT) technology. This Israeli health-tech company, based on the pioneering research of Prof. Noam Shomron of Tel Aviv University, has developed a method capable of identifying 250 hereditary genetic disorders from a simple maternal blood sample, ten times more than current NIPT capabilities. IdentifAI’s technology uses AI and machine learning to isolate fetal DNA and perform full genetic sequencing as early as nine weeks of pregnancy. This innovation represents a significant leap forward in prenatal health, offering parents earlier and more comprehensive insights into their baby's genetic health. Read it fully below. #genetics #prenatalcare #healthtech #healthinnovation #medtech #innovation

Current bedside pupillometry methods are limited by being intermittent, manual, and often ineffective in closed-eye conditions, which are common during sleep or anesthesia. There is an unmet need for continuous, non-invasive monitoring that can capture rapid pupil dynamics, crucial for assessing neurological function. Prof. Yuval Nir and Prof. Israel Gannot’s innovative technology addresses this by using touchless short-wave infrared (SWIR) imaging to measure pupil size and light reflex in both open and closed eyes, with high temporal resolution. This solution has potential applications in neurology, critical care, and sleep medicine, enabling real-time monitoring. To learn more about this technology and its potential industry applications, please contact Dr. Noam Greenspoon, VP Business Development Physcial Sciences at Ramot: noam.greenspoon@ramot.org #healthtech #medtech #healthinnovation #imaging #neurology #innovation

Tali Aloya, Ph.D., our VP Business Development Life Sciences, participated in the Next Pharma Tech Forum last week, hosted by Startup Nation Central in Tel Aviv. The event featured a panel, moderated expertly by Mati Gill, of industry leaders who discussed the critical role of partnerships in driving innovation in the pharma-tech space. Panelists included: Tehila Ben-Moshe, Founder and CEO of Biond Biologics Ltd, Anat Cohen-Dayag, President and CEO of Compugen, Ari Strasburg, CEO of 8400, Yael Pomerantz, Health Tech Sector Lead at Startup Nation Central, and Eden Eini, Ecosystem Growth Manager at Startup Nation Central. The panel offered insights into strategies, challenges, and success stories in forging impactful collaborations. It was an inspiring event, fostering connections and partnerships that will shape the future of healthcare innovation. #healthtech #pharmatech #medtech #healthcare #innovation #healthcareinnovation

Congratulations to Prof. Dan Peer, Prof. Ben Maoz, Prof. Dor Solomon, Prof. Gal Oestreicher-Singer, Prof. Michal Feldman, Dr. Ilia Kaminker, and Dr. Tzachi Hagai for being awarded the prestigious European Research Council (ERC) 2024 Consolidator Grant. Out of 17 recipients from Israel, 6 are from Tel Aviv University, exemplifying the exceptional research and innovation fostered at our institution. This esteemed grant supports leading researchers in advancing groundbreaking projects across diverse scientific fields. We are proud of you and your journey and wish you continuous growth and success. #grants #prestigiousgrants #ERC #innovation #research #researchinnovation #congratulations

Congratulations to NetaGenomiX, a Ramot spinoff, for achieving a significant milestone and securing funding from the Israel Innovation Authority רשות החדשנות. This prestigious recognition highlights the groundbreaking approach, developed by prof. Eilon Shani and Prof. Itay Meroz, in gene editing in plants and reinforces their leadership in advancing sustainable agricultural solutions. Wishing the team continued success as they drive innovation and shape the future of agri-tech. #agritech #geneediting #geneinnovation

Age-related macular degeneration (AMD) is the leading cause of blindness in Western countries, resulting in irreversible vision loss in advanced stages. Current treatments manage symptoms but do not provide a cure. Prof. adiel Barak, Prof. Dvir Tal, and Dr. Aya Barzelay MD PhD, have developed a novel solution using 3D bioprinting to create a three-layer retina-like structure that mimics the natural retina, supporting retinal cell survival and function. This approach, incorporating patient-specific extracellular matrix (ECM) hydrogels, offers a promising solution for restoring vision in AMD patients. To learn more about this innovative technology and its industry applications, please contact Tali Aloya, Ph.D., VP Business Development Life Sciences at Ramot: tali.aloya@ramot.org  #amd #blindness #healthtech #medtech #amdtreatment #bioprinting #innovation #healthinnovation #research #researchtechnology

Thank you, Ichilov Tel Aviv Medical Center, for inviting us to participate in your inspiring hackathon addressing critical healthcare challenges! Over 48 hours of intense creativity, 130 groundbreaking ideas were distilled into 12 exceptional projects. The winning concept, Mini ECMO Brain-Heart, led by Dr. Yishay Szekely in collaboration with Offir Loboda, a student from Tel Aviv University, stood out for its groundbreaking approach. This device bridges the gap between a patient’s collapse and hospital care by delivering oxygen to the brain through a single cannula inserted by paramedics in the field, preserving brain function for up to 30 minutes, and transforming out-of-hospital resuscitation. Our CEO, Ronen Kreizman, was honored to serve as one of the esteemed judges, sharing his expertise in evaluating these transformative ideas. A heartfelt thank you to Benjamin Soffer, Tel Aviv Medical Center, Ichilov Tech, BLEE Hackathons, Tel Aviv University, IMed TLV, Siemens, Eli Sprecher Omer Trivizki and everyone who contributed to creating such a vibrant platform for innovation. Together, you’ve set a new benchmark for healthcare solutions. #healthtech #medtech #healthinnovation #healthcare #healthcareinnovation #innovation #hackathon #groundbreaking

A study led by Prof. Illana Gozes of Tel Aviv University reveals gender differences in response to Davunetide, an experimental drug for neurodegenerative diseases like Alzheimer's, marked by TAU protein accumulation in brain neurons. Clinical trials with 144 older adults (76 women, 68 men) using a nasal spray showed men improving visual memory by 20%, up to 80% with higher doses. Women improved verbal attention memory by 10% and experienced reduced anxiety at higher doses, unlike declines seen in placebo-treated women. The findings highlight the importance of considering gender in drug development for brain disorders. Dr. Ronen Kreizman, CEO of Ramot, noted: "This study marks a new era in drug development, where gender becomes a key factor in clinical trial design and drug development. At Ramot, we are proud to support groundbreaking research like this, which pushes the boundaries of medicine and enables innovative treatments for severe diseases." #gender #genderresearch #drugdevelopment #breakthrough #groundbreakingresearch #neurodegenerativediseases #innovation #researchinnovation #clinicaltrialdesign